DexCom (DXCM) Projected to Release Earnings on Thursday

DexCom (NASDAQ:DXCM) is projected to release its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $0.6750 per share and revenue of $1.33 billion for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.09. DexCom had a net margin of 20.12% and a return on equity of 35.94%. The company had revenue of $1.31 billion for the quarter, compared to analysts’ expectations of $1.29 billion. During the same quarter in the previous year, the firm posted $0.48 EPS. DexCom’s revenue was up 13.1% on a year-over-year basis. On average, analysts expect DexCom to post $2.64 EPS for the current fiscal year and $3.08 EPS for the next fiscal year.

DexCom Price Performance

DexCom stock opened at $78.57 on Tuesday. DexCom has a 12 month low of $54.11 and a 12 month high of $92.59. The company has a current ratio of 1.73, a quick ratio of 1.43 and a debt-to-equity ratio of 0.47. The business’s 50 day simple moving average is $86.83 and its 200 day simple moving average is $74.40. The company has a market cap of $29.65 billion, a price-to-earnings ratio of 31.06, a PEG ratio of 1.31 and a beta of 1.48.

Insider Buying and Selling

In related news, EVP Michael Brown sold 1,700 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $85.48, for a total value of $145,316.00. Following the completion of the transaction, the executive vice president directly owned 98,185 shares of the company’s stock, valued at approximately $8,392,853.80. This trade represents a 1.70% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark Foletta sold 2,000 shares of DexCom stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total transaction of $170,640.00. Following the completion of the transaction, the director owned 48,852 shares of the company’s stock, valued at $4,168,052.64. This represents a 3.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 24,257 shares of company stock worth $2,049,173 in the last 90 days. 0.28% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of recent research reports. Piper Sandler reissued an “overweight” rating and issued a $95.00 target price (up from $88.00) on shares of DexCom in a research report on Friday, July 31st. Raymond James Financial reaffirmed a “strong-buy” rating and set a $94.00 price target on shares of DexCom in a research report on Friday, July 31st. Canaccord Genuity Group set a $90.00 price target on DexCom and gave the stock a “buy” rating in a research note on Monday, August 3rd. Mizuho set a $100.00 price objective on DexCom in a report on Tuesday, October 13th. Finally, BTIG Research lifted their price objective on DexCom from $90.00 to $96.00 and gave the stock a “buy” rating in a report on Monday, October 12th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $92.43.

About DexCom

DexCom, Inc develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets.